Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
23.06.2014 | 13:01
www.prnewswire.com/news-releases/alimera-sciences-iluvien-receives-marketing-authorization-in-italy-for-the-treatment-of-chronic-diabetic-macular-edema-264213461.html
PR Newswire
Alimera Sciences' ILUVIEN Receives Marketing Authorization In Italy For The Treatment Of Chronic Diabetic Macular Edema
ATLANTA, June 23, 2014 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
The ILUVIEN marketing authorization notice was published on June 18 in the Gazzetta Ufficiale della Repubblica Italiana, the official journal of record of the Italian government. Designated a C Class product in Italy, ILUVIEN will be available initially to private paying patients. Alimera is pursuing H Class designation for ILUVIEN with the Italian regulatory authorities, which, if granted, would expand patient access to the product.
The Italian authorization is the seventh national approval in the EU, preceded by Austria, theUnited Kingdom, Portugal, France, Germany and Spain. ILUVIEN is commercially available in the U.K. and Germany.
"ILUVIEN has now been granted marketing authorizations in all seven EU countries in which we initially applied," said Dan Myers, Alimera's president and chief executive officer. "Additionally, we are engaged in a Repeat Use Procedure through Mutual Recognition (MRP) to obtain a positive opinion for approval from another10 EU countries."
"This approval is important news for patients in Italy with DME whose disease has evolved to chronic DME," said Dr. Stanislao Rizzo, chairman of the U. O. Chirurgia Oftalmica, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. "ILUVIEN is a valuable option for patients who are not sufficiently responding to other treatments."
and we anticipate the effective date of the proposed actions to be June 14, 2014, the record date, or as soon thereafter as practicable in accordance with applicable law, including the Nevada Revised Statutes.
GW Pharmaceuticals plc (NASDAQ: GWPH) reported Q1 EPS of ($0.04), $0.44 better than the analyst estimate of ($0.48).
www.streetinsider.com/Corporate+News/GW+Pharmaceuticals+%28GWPH%29+Posts+Q1+Loss+of+4cShare%3B+Epidiolex+IND+Now+Open+for+Phase+23/9453712.html
Arsenal Energy Inc. Announces 2014 First Quarter Results and Increased Quarterly Dividend
de.advfn.com/p.php?pid=nmona&article=62096664
GW Pharmaceuticals Appoints Dr. Kenneth Sommerville as VP, Clinical Science
GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
Intraday Stock Chart
Today : 6 Mai 2014
Click Here for more GW PHARMACEUTICALS PLC Charts.
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Kenneth Sommerville MD to the newly created position of VP, Clinical Science, based in the United States.
Dr. Sommerville will play an important role in the clinical development, medical affairs, and regulatory activities related to the Company's epilepsy programs including the ongoing development of Epidiolex®, GW's product candidate for Dravet and Lennox-Gastaut syndromes. He will also support the late stages of the completion of the investigational plan for Sativex® in cancer pain.
"We are delighted to announce this important appointment and welcome Ken's extensive industry experience and therapeutic expertise in support of our rapidly evolving programs in the United States," stated Justin Gover, GW's Chief Executive Officer. "We have received significant interest from physicians and parents regarding Epidiolex for childhood epilepsy and with the GW-sponsored pivotal trials expected to commence in the second half of this year, Ken will play a leading role in the clinical development of this important product in the U.S. His expertise and depth of knowledge in product development and regulatory matters will serve GW well as we seek to advance Epidiolex through clinical trials and, if successful, obtain FDA approval as rapidly as possible."
Dr. Sommerville is a board-certified neurologist and joins GW with a significant record of achievement including twenty-three years of experience in the pharmaceutical industry. He has had senior roles at UCB/Schwarz Pharma where he led clinical and regulatory programs in epilepsy and other neurological product development initiatives including NDA submissions to FDA and EMEA for multiple compounds. Most recently, Dr. Sommerville served as Vice President of Clinical Sciences at Pfizer, Inc. where he was Global Clinical Lead for opioids and led a team of physicians and scientists in the development of abuse-deterrent opioids. He also has led teams in multiple medical and scientific areas including, but not limited to, indications of complex partial seizures, basic and rapid infusion of an intravenous anti-convulsant, painful diabetic neuropathy, migraine prophylaxis, Parkinson's disease, bipolar disorder, personality disorders, and schizophrenia. Dr. Sommerville has made major contributions to over twenty NDA submissions for both the FDA and EMEA and is recognized as an authority in drug development, especially anti-epileptic drugs, pain, and abuse-deterrent opioids.
"This is an exciting time to be joining GW, with a number of important products currently under development for patients in the United States including Sativex and Epidiolex. Specifically, I believe that Epidiolex has the potential to become an important new therapeutic option for children suffering with intractable epilepsy, an area of significant unmet need," said Dr. Sommerville. "I look forward to working with the GW team to develop new treatments from their proprietary cannabinoid platform."
Dr. Sommerville earned a M.D. degree from Jefferson Medical College in Philadelphia, Pennsylvania and is an Adjunct Assistant Professor of Medicine at the Duke University Medical Center in Durham, North Carolina. Dr. Sommerville was in the private practice of neurology for 11 years prior to entering the pharmaceutical industry.
PR Newswire·Mehr PR Newswire
GrowLife Establishes Board Governance Policies, Restructures Compensation for Independent Directors
WOODLAND HILLS, Calif., April 30, 2014 /PRNewswire/ --GrowLife, Inc. (PHOT), the recognized leader in specialty hydroponics and an essential facilitator of the grower marketplace, announced an initial component of its GrowLife 2.0 go-forward plan with the creation of stronger governance policies at the Board level, the restructuring of Board compensation and the creation of guiding principles for the long-term growth of the company.
A new compensation plan for independent Directors on GrowLife's Board has been proposed to replace the stock award plan originally established in August 2012. The initial step in the implementation of the proposed compensation plan is the agreement by all four independent directors of GrowLife to cancel their respective 500,000 share stock grants for Q1 2014 issued pursuant to the August 2012 plan.
"Upon review of director compensation, the independent directors recognized the importance of making this change for the good of the company, and called-upon themselves to serve as leadership examples," commented Marco Hegyi, President and Board Director. "This is the first of several strategic announcements GrowLife will make over the next few weeks, as key components of our GrowLife 2.0 plan."
The proposed plan shifts compensation away from historical stock awards, and moves it toward incenting/rewarding independent Directors for overseeing the long-term growth and expansion of the company. Director compensation will become more equitable and in-line with the company's performance.
"This long-term incentive plan will align Board compensation with company performance," said Sterling Scott, GrowLife's Chairman and CEO. "It recognizes the importance of strong governance, industry leadership and a long-term view of what's right for the company and the industry. That tenet is a fundamental guiding principle of our GrowLife 2.0 strategy."
Also fundamental is stronger business acumen shared throughout the company, and compliance policies that ensure GrowLife's business practices and investment strategies are in full compliance with regulatory requirements and market dynamics. To provide oversight and clear direction, the Board has established four essential committees:
Audit Committee to provide greater oversight on all compliance matters;
Compensation Committee to review compensation programs, specifically around stock incentive plans;
Nominating Committee to identify and screen additional board members who are committed to the long-term growth of the company;
Mergers and Acquisitions Committee to guide purchasing and investments by the company
About GrowLife, Inc. (PHOT). GrowLife (www.growlifeinc.com) is the recognized leader in specialty hydroponics and an essential facilitator of the grower marketplace, through our nationwide retail network, as well as online sites Greners.com, Phototron.com and StealthGrow.com.
MoneyJames, indeed very good question :(
We believe a minimum of $350,000 is still needed to complete the EEG device, which will cover costs associated with the SDK (operating system), the design work to create a sleek, consumer-friendly final product and updates on the hardware including Bluetooth wireless updates. We have announced our desire to partner with a larger technology firm to invest in the completion of the EEG headset in return for a negotiated interest in the product. If successful, we will not need to raise this capital to complete the project. If we are not successful in attracting a financial partner to assist in the completion of the EEG headset, we plans to raise funds by means of an equity offering to raise the necessary capital to complete the project.
Mind Solutions currently has a need of approximately $20,000 per month to sustain operations until sales of the software and anticipated sales of the EEG headset increase.
As of December 31, 2013, Mind Solutions had an accumulated deficit during development stage of $23,385,789, which included a net loss of $22,142,473 reported for the year ended December 31, 2013. Also, during the year ended December 31, 2013, we used net cash of $388,177 for operating activities. These factors raise substantial doubt about our ability to continue as a going concern.
www.sec.gov/Archives/edgar/data/1136711/000126246314000299/mindsolutions201310k.htm
TOP NEWS
US over-counter trading tightens reporting, other standards
Wed, Mar 26 16:15 PM EDT
NEW YORK, March 26 (Reuters) - OTC Markets, the operator of three U.S. over-the-counter equity markets, is rolling out tighter reporting standards and eligibility requirements for its venture-stage market to crack down on stock scams and bolster transparency, the company said on Wednesday.
On May 1 for its OTCQB market, OTC Markets will introduce a new minimum one-cent bid price requirement and will require the company's chief executive or chief financial officer to certify that its reporting obligations are current and that disclosures about shareholdings, officers and corporate profile are correct.
The bid requirement, in which stocks must have been quoted for at least 1 cent daily over a 30-day period or be dropped from the market, aims to ferret out companies that fall prey to dilutive stock fraud schemes and promotions, OTC Markets said.
OTC Markets also will charge a one-time $2,500 fee for new applicants and an annual $10,000 fee for companies trading on its markets.
Foreign companies that are listed on a qualified stock exchange and are current in their U.S. reporting obligations will be allowed to trade on OTCQB, OTC Markets' middle-tier marketplace. In the past, they traded on the lowest "pink" tier.
On Tuesday, the two most actively traded stocks on OTC Markets on Tuesday were French dairy products maker Danone SA and Swiss pharmaceuticals Roche Holding AG .
Trading volume on OTC Markets was 20.1 billion shares on Tuesday, about three times that of all U.S. stock exchanges and other trading venues. But the value traded, $1.4 billion, paled in comparison with the $263.4 billion executed on the other exchanges and venues, data from BATS Global Markets showed. (Reporting by Herbert Lash)
uk.reuters.com/article/2014/03/26/otcmarkets-reforms-idUKL1N0MN13N20140326
This company is worth 410 euros in the London Exchange.
Pounds not euros
They don`t have euros
Doesn`t matter, 410 in the one or the other currency would be nice. :o
In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH [FREE Stock Trend Analysis]) and raised the price target from $77.00 to $97.00.
Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.
The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”
GW Pharmaceuticals closed at $57.71 on Thursday. Shares have traded as high as $64.73, up 12.16% on Friday. This has been the biggest intraday gain since January 9.
www.benzinga.com/analyst-ratings/analyst-color/14/02/4292155/piper-sees-meaningful-utility-from-gw-phamaceuticals-cbd
- Q1 losses widen while revenues improve
- Expect Sativex revenues to return to growth in 2014
- Robust pipeline of cannabinoid products
AIM-listed pharmaceutical company GW Pharmaceuticals said losses for the first quarter of 2014 widened as revenue improved.
The biopharmaceutical firm, known for its multiple sclerosis treatment Sativex, said pre-tax losses widened to $3.5m for the three months to December 31st compared to a loss of $2.4m a year earlier.
Total revenue for the period rose to £7.5m compared to £5.2m before.
Chief Executive Officer Justin Gover said: "In addition to our orphan epilepsy programme, as we move through 2014, we expect a significant amount of milestones, including Phase 3 cancer pain data for Sativex as well as important clinical progress across our robust pipeline of cannabinoid product candidates."
The group, which last year received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis, said it continues to expect Sativex revenues to return to growth in 2014. Sativex is approved for use in 25 countries.
Furthermore, it said upon the first patient being randomised into the planned US Phase 3 MS spasticity trials, it expects to receive a $5m milestone payment from pharmaceutical company Otsuka.
Cash and cash equivalents as at December 31st of £35.3m compared to £38.1m as at September 30th.
sharecast.com/news/gw-pharmaceuticals-operating-losses-widen/21461332.html
One of the advantages of having wide Wall Street coverage is the ability to constantly screen even the smallest tidbits of research that is put out each day. Many times firms will put out long-winded, excruciating detail that includes massive graphs and page after page of balance sheet data. Sometimes the data looks small in quantity but is actually huge in quality.
The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have gleaned some interesting morsels that could be huge as the year wears on.
...
GW Pharmaceuticals PLC (NASDAQ: GWPH) recently entered an agreement with Ipsen, a French pharmaceutical company to promote and distribute Sativex, its controversial cannabis spray, in Latin America (excluding Mexico and the Caribbean islands). Sativex is used to treat spasticity in multiple sclerosis patients, and has been approved in 24 countries, primarily across Europe. The company also announced the pending use patent on Epidolex could extend exclusivity of the potential migraine drug until 2032. This is another cannabis related extract. The Piper Jaffray price target for the stock is $73. The Thomson/First Call target is set at $54.50. The stock closed Wednesday at $51.
...
247wallst.com/healthcare-business/2014/01/16/piper-jaffray-has-four-biotech-stocks-to-buy-with-huge-potential/#ixzz2qZJw4K8d
Who presses permanently the course on 3 down with 100 pieces?
The 7th time already is
Are they still drunk from New Year's Eve ???
From the blog:
January 5, 2013
Happy New Year and this will truly be a Happy New Year.....
Alimera guys didnt conduct new study for some odd reason. Not Psivida. The clinical trials of ILUVIEN are conducted by Alimera
The FDA previously rejected Iluvien in December 2010 and November 2011 and requested new clinical trials, which Alimera chose not to conduct.
www.thestreet.com/_nasdaq/story/12073818/1/alimera-psivida-eye-drug-rejected-by-fda.html?&cm_ven=NASDAQ&cm_cat=FREE&cm_ite=NA
Trading Halt
This applies probably only the European markets?
pSivida expects to life the halt pending its release of a press release in the U.S. today between 6.30 and 9.00 am ET.
www.proactiveinvestors.com.au/companies/news/49259/psivida-corporation-awaits-fda-decision-on-its-eye-disease-treatment-49259.html
07:01 EDT GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock.
-----
10:38 EDT GW Pharmaceuticals soars after analyst nearly triples price target
Shares of Britain's GW Pharmaceuticals (GWPH) are jumping after a Lazard Capital analyst wrote that the company has one of the most compelling opportunities he's ever seen, and nearly tripled his price target on the stock. WHAT'S NEW: GW's CBD, a drug derived from the cannabis plant, has significantly helped some epilepsy patients to whom it has been administered, Lazard Capital analyst Joshua Schimmer wrote in a note to investors earlier today. Although not all the refractory childhood seizure patients who have taken the drug have improved, evidence suggests that the treatment does have "an antiseizure effect," the analyst believes after speaking with multiple experts. Moreover, "there is an enormous unmet need" for such an antiseizure treatment, and specialists appear to be extremely interested in CBD, Schimmer contended. He hiked his price target on GW to $65 from $22, and kept a Buy rating on the shares. TODAY'S PRICE ACTION: In mid-morning trading, GW rallied $5.95, or 24%, to $30.65.
www.theflyonthewall.com/permalinks/entry.php/GWPHid1896862/GWPH-GW-Pharmaceuticals-soars-after-analyst-nearly-triples-price-target
News Breaks
October 7, 2013
07:01 EDT GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock.
www.theflyonthewall.com/permalinks/entry.php/GWPHid1896615/GWPH-GW-Pharmaceuticals-price-target-raised-to--from--at-Lazard-Capital
sorry, wrong thread
Patriot Wins Patent Infringement Suit Against HTC Corporation
online.wsj.com/article/PR-CO-20131003-910279.html
The deal with Alimera in terms of outside The United States includes 20% net profits on a country by country basis and pSivida has full audit rights. If Alimera decides to partner out the European commercialization then PSDV is entitled to 33 percent of any upfront and or milestone payments and 20 percent of whatever Alimera gets in royalties.
www.biomedreports.com/2012062798494/psivida-small-cap-ophthalmology-based-biotech-positioned-for-long-term-growth.html
Why buying Alimera?
Alimera has to pay 25 Mio at Psivida if the FDA is positiv.
Psivida is the better invest. imo
Patent Filed
October 2013
Patent Filed
Rival announces that it has completed filing of a PCT (Patent Cooperation Treaty) patent application for its TRU technology. The PCT patent provides a process to obtain patents in various jurisdictions, and protects the technology on a worldwide basis from the date of filing. TRU technology is now considered patent pending, and the company will update as it receives comments from the patent office. A final patent approval is expected to take 6 months.
www.rvti.com/news.html
www.asx.com.au/asxpdf/20131001/pdf/42jr3ndrbcd0v7.pdf
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending ILUVIEN as an option for the treatment of chronic diabetic macular edema (DME) that is insufficiently responsive to available therapies in pseudophakic eyes (those that have already undergone cataract surgery). This recommendation reverses the final draft guidance previously issued by NICE with respect to this subgroup of chronic DME patients.
NICE's final guidance recommending ILUVIEN to the National Health Service (NHS) is expected to be published in November 2013, which would result in NHS reimbursement in England and Wales under the patient access scheme submitted by Alimera Sciences, pSivida's licensee.
Today after market close ...
its financial results for the fourth quarter and fiscal year 2013 will be released after the market close on Wednesday, September 25, 2013
19.08.2013 Epigenomics AG secures financing of up to EUR 5m
www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-ag-sichert-finanzierung-von-bis-zu-eur-5-mio.html
Epigenomics – Conference Call on August 7, 2013
Operator
Good afternoon ladies and gentlemen, I would like to welcome you to the epigenomics half-year, 2013,
financial results and operational update conference call. At this time, all participants have been placed
on a listen-only mode. The floor will be open for questions following the presentation. I would now like
to turn the call over to Thomas Taapken, CEO and CFO at Epigenomics. You may begin your conference
call.
www.epigenomics.com/fileadmin/site_files/00_NEWS/20_investor_relations/20_finance_information/2013/Transcript_Conference_Call_August_7__2013.pdf
Don`t know what's going wrong.
I bought some in Germany`FRA
Yesterday`s news:
Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights
07.08.2013
Berlin, Germany, and U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.
Revenue in Q2 2013 increased by 120% to EUR 343 thousand compared to Q2 2012
Operating costs decreased by 44% to EUR 2,098 thousand over Q2 2012
EBIT in Q2 improved by 53% to EUR -1,607 thousand compared to Q2 2012
Net cash flow in H1 2013 positive due to successful capital increase in January
Level 1 ADR program established
www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-ag-gibt-finanzergebnisse-des-ersten-halbjahres-und-zweiten-quartals-2013-bekannt-und-ber.html
jupp
Methuselah Foundation
www.methuselahfoundation.org/
Announcing: NewOrgan Prize
To encourage and incentivize this scientific breakthrough
Methuselah Foundationhas created the New Organ Prize.
The dollar amount oft his award will grow with donations
from the general public. It will be awarded for successfully
constructing a whole new organ – heart, kidney, lung,
pancreas or liver – from a patient’s own cells. The
organs must have functioned properly for two years in
order for the award to be granted (more details&specific
requirements are available to potential competitors).
and the winner will be...?
Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
22.07.2013
CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates
Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC mortality by 61% at optimal screening uptake rates
Septin9 based screening shown to be cost-effective over no screening
Berlin, Germany, and U.S.A., July 22, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced findings from a health economic study by Prof. Uri Ladabaum, M.D., M.S., et al. from the Division of Gastroenterology and Hepatology, Stanford University School of Medicine, USA.
According to the study, Septin9 testing provides potential for saving lives while being health economically beneficial as an attractive screening alternative to established methods for a population that would otherwise be non-compliant to colorectal cancer screening.
The study, which was published in “Cancer Epidemiology, Biomarkers & Prevention”, concluded that Septin9 tests would decrease CRC incidence by 41% and CRC mortality by 61% assuming optimal uptake. In addition, Septin9 tests have the potential to demonstrate significant economic benefits at acceptable costs by increasing screening rates and improving adherence over time compared to other strategies. At 75% adherence with the blood-based Septin9 test, compared to under 20% with stool-based tests (FIT) per screening cycle, Septin9 based CRC screening would be cost-effective. In the comparison, current FIT tests would be more effective and less costly than all other alternatives, assuming optimal uptake, adherence and follow-up, but this has not yet been achieved in practice.
“Colorectal cancer is the third most common cancer globally and the second most common cancer in industrialized countries. As observed in other cancer indications, screening and early detection of cancers could decrease mortality significantly. Although established screening strategies are very effective and cost efficient, compliance rates are devastatingly low due to the partly invasive and/or uncomfortable nature of the established screening methods. At least one of three eligible US citizens does not undergo CRC screening, resulting in more than 60% of CRC cases being detected in late, symptomatic stages,” explained Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “CRC screening with a convenient blood test has the potential to significantly improve screening uptake and adherence and ultimately reduce CRC incidence and mortality, as well as resulting healthcare cost.”
The basis for comparison between different screening methods in the Ladabaum study were the published results of the PRESEPT study, run with a prototype version of the Septin9 assay, and historical FIT data. There were no direct comparison data between the two methods at the time. Epigenomics recently conducted a head-to-head comparison study between its Epi proColon® test, currently under PMA review by the FDA, and FIT demonstrating non-inferiority of Epi proColon® to FIT with respect to sensitivity. The achieved sensitivity for Epi proColon was 73%, compared to 68% for FIT.
- Ends –
Contact Epigenomics AG
Epigenomics Establishes American Depositary Receipt (ADR) Program
09.07.2013
Epigenomics ADRs can be traded on US over-the-counter (OTC) market effective as of July 9, 2013
ADR ticker symbol EPGNY
1 ADR represents 5 ordinary company shares
Berlin, Germany, and U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that the Company has established a Level 1 ADR program in the U.S.A. BNY Mellon has been appointed as the depositary bank for the ADR program. ADRs of Epigenomics are US dollar negotiable certificates representing ordinary shares of the Company at a ratio of five ordinary shares to one Epigenomics ADR. Epigenomics ADRs can be traded on the US OTC market effective as of July 9, 2013 under the ticker symbol EPGNY. Ordinary Epigenomics shares are traded in Frankfurt Prime Standard, Germany, under the ticker symbol ECX.
CEL-SCI and NIAID Publish Data Showing That CEL-SCI's LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu Strain
www.nasdaq.com/press-release/cel-sci-and-niaid-publish-data-showing-that-cel-scis-leaps-technology-halted-progression-of-lethal-influenza-in-three-different-influenza-virus-strains-including-a-drug-resistant-and-a-2009-pandemic-flu-strain-20130725-00446
An expected outcome from the program is a greater set of preliminary results to justify the granting of additional government research grants in the 3D bioprinting space. Organovo and Methuselah are confident that the program can become a springboard for much broader productive use of bioprinting in a number of areas of biological research.
Sounds good to me. Think there will come a lot of fantastic results.
jupp